{"entity":{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","aka":[],"tldr":"Developed the MANAFEST assay to track the tumour-specific T cells that immunotherapy awakens.","summary":"Kellie N. Smith is Associate Professor of Oncology at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a T-cell immunologist known for developing the MANAFEST assay, which detects and tracks the mutation-associated neoantigen-specific T cells that immunotherapy awakens. Her selected paper describes MANAFEST as a functional assay for neoantigen-specific T cells. She now applies these assays to neoadjuvant immunotherapy trials, with relevance to checkpoint inhibitors and personalised neoantigen vaccines.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/kellie-smith"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Associate Professor of Oncology; Bloomberg~Kimmel Institute","institutionId":"johns-hopkins","specialisms":["T-cell immunology","Neoantigen-specific T cells","MANAFEST assay"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/kellie-smith"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D"}],"papers":[{"title":"MANAFEST: a functional assay to detect and track mutation-associated neoantigen-specific T cells","journal":"Cancer Immunology Research","year":2018}]},"route":"/people/kellie-smith/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"term":[{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"}],"journal":[{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/"}]}}